FDA wants to rewrite the clinical trial playbook. The hard part starts now

FDA announced Operation TrialBlazer on August 6, proposing an Expedited IND Pilot that could shorten the path from identifying a drug to testing it in people for the first time. Federal officials said the changes could remove six to twelve months from early development.

The agency also clarified when one adequate and well controlled pivotal trial, supported by confirmatory evidence, may be sufficient to establish effectiveness. The proposal does not lower the legal standard for approval, but it could change how sponsors assemble the evidence used to meet it.

How the expedited IND pilot would work

The proposed Expedited IND Pilot would focus on the period before a first in human phase 1 study. FDA is seeking public comment on the design of the program, including which drugs should qualify and how the agency should work with sponsors.

Sponsors would still need to provide the manufacturing, toxicology and clinical protocol information required for an investigational new drug application. FDA describes the initiative as an effort to remove unnecessary regulatory work while maintaining its existing standards for safety and effectiveness.

When one pivotal trial may be enough

Federal law allows FDA to find substantial evidence of effectiveness from one adequate and well controlled clinical investigation plus confirmatory evidence. The agency's revised guidance explains the factors it may consider when deciding whether that approach is appropriate.

Confirmatory support may include clinical evidence from another use of the drug, measurements showing its effect in the body, information from related drugs or other data that independently support the pivotal result. FDA said the amount and type of evidence will depend on the product, disease and strength of the main study.

Implementation questions remain

FDA has not yet published final eligibility rules, performance measures or a start date for the expedited pilot. Those details will determine how many sponsors can use it and whether the projected time savings are achieved.

The agency also plans to expand the use of newer research methods, including organ on chip systems, computational models and data collected outside conventional trials. Sponsors will need to show that any such evidence is reliable and relevant to the regulatory question being addressed.